WINTON GROUP Ltd Boosts Stock Position in Arcus Biosciences, Inc. (NYSE:RCUS)

WINTON GROUP Ltd lifted its position in Arcus Biosciences, Inc. (NYSE:RCUS) by 3.3% in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 59,137 shares of the company’s stock after purchasing an additional 1,872 shares during the quarter. WINTON GROUP Ltd owned about 0.07% of Arcus Biosciences worth $901,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently modified their holdings of RCUS. American Century Companies Inc. raised its position in Arcus Biosciences by 22.5% during the 2nd quarter. American Century Companies Inc. now owns 70,917 shares of the company’s stock worth $1,080,000 after buying an additional 13,019 shares during the last quarter. ClariVest Asset Management LLC purchased a new position in shares of Arcus Biosciences during the second quarter worth $260,000. BNP PARIBAS ASSET MANAGEMENT Holding S.A. lifted its position in Arcus Biosciences by 8.7% during the second quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 744,298 shares of the company’s stock valued at $11,336,000 after purchasing an additional 59,273 shares during the period. Innealta Capital LLC purchased a new stake in Arcus Biosciences in the second quarter valued at $66,000. Finally, Louisiana State Employees Retirement System grew its position in Arcus Biosciences by 2.6% during the 2nd quarter. Louisiana State Employees Retirement System now owns 27,500 shares of the company’s stock worth $419,000 after purchasing an additional 700 shares during the period. Institutional investors and hedge funds own 92.89% of the company’s stock.

Arcus Biosciences Stock Performance

NYSE:RCUS opened at $16.90 on Tuesday. The company has a fifty day moving average of $15.90 and a two-hundred day moving average of $16.28. Arcus Biosciences, Inc. has a fifty-two week low of $12.95 and a fifty-two week high of $20.60. The stock has a market capitalization of $1.55 billion, a PE ratio of -5.43 and a beta of 0.90.

Arcus Biosciences (NYSE:RCUS) last issued its quarterly earnings results on Thursday, August 8th. The company reported ($1.02) earnings per share for the quarter, meeting analysts’ consensus estimates of ($1.02). Arcus Biosciences had a negative net margin of 100.81% and a negative return on equity of 42.86%. The firm had revenue of $39.00 million for the quarter, compared to analyst estimates of $26.24 million. During the same period last year, the company posted ($1.04) EPS. Arcus Biosciences’s quarterly revenue was up 34.5% compared to the same quarter last year. Research analysts forecast that Arcus Biosciences, Inc. will post -3.03 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on the company. Truist Financial decreased their price objective on Arcus Biosciences from $50.00 to $44.00 and set a “buy” rating for the company in a report on Monday, June 24th. Cantor Fitzgerald restated an “overweight” rating on shares of Arcus Biosciences in a research report on Friday, August 9th. Wedbush reaffirmed an “outperform” rating and set a $30.00 target price on shares of Arcus Biosciences in a report on Friday, August 9th. Evercore ISI raised shares of Arcus Biosciences to a “strong-buy” rating in a report on Friday, August 9th. Finally, Barclays cut their price objective on shares of Arcus Biosciences from $35.00 to $25.00 and set an “overweight” rating for the company in a report on Monday, July 8th. Seven investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, Arcus Biosciences presently has a consensus rating of “Buy” and an average price target of $35.71.

Arcus Biosciences Company Profile

Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies.